Expert Perspectives on the Current Role of CAR-T Cell Therapy in Patients with Mantle Cell Lymphoma (MCL)

A study showed that a treatment regimen called BOVen was safe and effective in producing responses in older patients with mantle cell lymphoma.

The FDA has approved the CAR T-cell therapy liso-cel for the treatment of patients with mantle cell lymphoma.

Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.

In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.

Technology plays a pivotal role in enhancing precision medicine within cancer care.

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.